More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Almost all of us who have practiced oncology for years have encountered situations where we have had to counsel caregivers and guide them throughout their loved ones’ journeys. We have faced patients who took complementary therapies to an extreme; some to a point where they wouldn’t share what they were taking for fear that we might demand they stop.
